Analyst Price Targets — BBOT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 11, 2026 9:15 am | John Newman | Canaccord Genuity | $23.00 | $7.66 | TheFly | BridgeBio Oncology initiated with a Buy at Canaccord |
| February 10, 2026 9:13 pm | Laura Prendergast | Stifel Nicolaus | $23.00 | $10.84 | TheFly | BridgeBio Oncology initiated with a Buy at Stifel |
| January 9, 2026 11:29 am | — | Raymond James | $24.00 | $13.30 | TheFly | BridgeBio Oncology initiated with an Outperform at Raymond James |
| January 8, 2026 12:46 pm | — | Morgan Stanley | $18.00 | $12.92 | TheFly | BridgeBio Oncology price target lowered to $18 from $20 at Morgan Stanley |
| December 5, 2025 12:36 pm | — | Morgan Stanley | $20.00 | $11.54 | TheFly | BridgeBio Oncology initiated with an Overweight at Morgan Stanley |
| September 17, 2025 10:59 am | — | Leerink Partners | $25.00 | $10.79 | TheFly | BridgeBio Oncology initiated with an Outperform at Leerink |
| September 15, 2025 10:15 am | Robert Burns | H.C. Wainwright | $27.00 | $9.73 | TheFly | BridgeBio Oncology initiated with a Buy at H.C. Wainwright |
| September 4, 2025 10:10 am | — | Oppenheimer | $23.00 | $10.08 | TheFly | BridgeBio Oncology initiated with an Outperform at Oppenheimer |
| August 15, 2025 11:03 am | Biren Amin | Piper Sandler | $21.00 | $9.70 | TheFly | BridgeBio Oncology initiated with an Overweight at Piper Sandler |
Latest News for BBOT
BridgeBio Oncology Therapeutics remains a Buy, despite a >30% decline since prior coverage, supported by three promising KRAS/RAS-targeted drug candidates. BBOT's lead asset, BB-8520, showed a 65% objective response rate and 100% disease control in KRAS G12C NSCLC, exceeding results from approved competitors. Further mature data readouts for BBOT's pipeline are expected in 2H26, representing key catalysts for share…
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the first quarter ended March 31, 2026, and provided a business update, including highlights of pipeline progress.
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on May 10, 2026 under BBOT's 2025 Inducement Plan as a material inducement to the employment of one individual hired by BBOT in March 2026.
Pre-Market Stock Futures: Futures are trading mixed as we get set to start the new trading week, as reports indicate that President Trump declined Iran's counteroffer for peace. This comes after a remarkable Friday, when stocks roared to record highs, driven primarily by a stronger-than-expected April jobs report that eased economic concerns and by a... Here Are Monday's Top Wall Street Analyst Research Calls: Dell…
BBO-11818 targets KRAS in both its ON (active GTP-bound) and OFF (inactive GDP-bound) states, potently suppressing MAPK signaling and inhibiting cell proliferation in KRAS-mutant cell lines
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BBOT.
U.S. House Trading
No House trades found for BBOT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.